New advice on contraception and pregnancy was published on 20 February 2019 by MHRA
Date: 14 Mar 2019
Type: Sexual and Reproductive Health News
The MHRA has released some new guidance for health care providers on the use of Carbimazole during pregnancy.
The guidance states that, “Carbimazole is associated with an increased risk of congenital malformations, especially when administered in the first trimester of pregnancy and at high doses. Women of childbearing potential should use effective contraception during treatment with carbimazole.” (MHRA, February 2019)
Clinicians are advised that the use of the drug during pregnancy when ‘clinically indicated’ and after a risk assessment has taken place, at the lowest effective dose.